JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.65 0.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.63

Max

4.74

Põhinäitajad

By Trading Economics

Sissetulek

-39M

-44M

Müük

9.8M

62M

Kasumimarginaal

-70.929

Töötajad

702

EBITDA

4M

-263K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+34.99% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

26M

587M

Eelmine avamishind

4

Eelmine sulgemishind

4.65

Uudiste sentiment

By Acuity

50%

50%

179 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Australian Flash PMI Bounce in April Conceals Deeper Worries

22. apr 2026, 23:33 UTC

Tulu

SK Hynix Posts Record Quarterly Results Amid AI Boom

22. apr 2026, 22:40 UTC

Tulu

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:11 UTC

Tulu

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22. apr 2026, 21:01 UTC

Tulu

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22. apr 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22. apr 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22. apr 2026, 23:34 UTC

Market Talk
Uudisväärsed sündmused

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22. apr 2026, 23:16 UTC

Tulu

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22. apr 2026, 23:15 UTC

Tulu

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22. apr 2026, 22:54 UTC

Tulu

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22. apr 2026, 22:52 UTC

Tulu

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22. apr 2026, 22:51 UTC

Tulu

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22. apr 2026, 22:31 UTC

Tulu

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22. apr 2026, 22:30 UTC

Tulu

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22. apr 2026, 22:30 UTC

Tulu

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22. apr 2026, 22:29 UTC

Tulu

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22. apr 2026, 22:28 UTC

Tulu

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22. apr 2026, 22:27 UTC

Tulu

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22. apr 2026, 22:06 UTC

Market Talk
Tulu

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22. apr 2026, 21:47 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:37 UTC

Tulu

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22. apr 2026, 21:34 UTC

Tulu

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22. apr 2026, 21:29 UTC

Tulu

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22. apr 2026, 21:20 UTC

Market Talk
Tulu

Tesla Expands Manufacturing to Chips -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

34.99% tõus

12 kuu keskmine prognoos

Keskmine 6.25 USD  34.99%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

179 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat